Endogena Therapeutics

Endogena Therapeutics is a biotechnology company dedicated to developing endogenous regenerative medicines to repair and regenerate tissues and organs. Its approach has the potential to transform the treatment of degenerative diseases associated with aging and genetic disorders. The company has developed an ophthalmic suspension orphan drug, EA-2353, for the treatment of retinitis pigmentosa. Our novel drug discovery approach is based on the concept of selectively modulating these endogenous cells to achieve controlled tissue repair through small molecules.